A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics
(firmenpresse) - HONG KONG -- (Marketwire) -- 01/13/12 -- Today, introduced featured coverage of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Nektar Therapeutics (NASDAQ: NKTR). Full research reports are available to readers at: .
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Achillion Pharmaceuticals, Inc. for its current position within the healthcare industry. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. A copy of this report featuring Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is available at: .
Bollinger Report is featuring Nektar Therapeutics for its changing role within the healthcare industry. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The Company's product pipeline consists of drug candidates across a range of therapeutic areas, including oncology and pain. To download researches and analysis on Nektar Therapeutics (NASDAQ: NKTR) we welcome investors to visit: .
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.01.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 103961
Anzahl Zeichen: 0
contact information:
Town:
HONG KONG
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics"
steht unter der journalistisch-redaktionellen Verantwortung von
Bollinger Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
